ASH Archives -

bluebird bio has presented long-term data from its Zynteglo one-time gene therapy for the blood disorder beta-thalassaemia, as

Bluebird trumpets long-term data from beta-thalassaemia gene therapy

https://pharmaphorum.com/news/bluebird-trumpets-long-term-data-from-beta-thalassaemia-gene-therapy/

Nearly half of patients with advanced lymphoma treated with Gilead/Kite’s CAR-T therapy Yescarta were alive after three years,

Nearly half of lymphoma patients alive after Gilead’s CAR-T therapy

https://pharmaphorum.com/news/nearly-half-of-lymphoma-patients-alive-after-gileads-car-t-therapy/

Paul Tunnah asks whether medical meetings will remain relevant in a digital world, and how they might adapt.

Medical meetings: Blockbuster or Netflix?

https://pharmaphorum.com/views-and-analysis/medical-meetings-blockbuster-or-netflix/

A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have

Celgene scores at ASH18 with double luspatercept data

https://pharmaphorum.com/news/celgene-scores-at-ash18-with-double-luspatercept-data/

Roche faces competition against its blockbuster haematology drug

As rituximab biosimilars close in, Roche showcases Gazyva superiority

https://pharmaphorum.com/news/rituximab-biosimilars-close-roche-showcases-gazyva-superiority/

Study of nine patients produce encouraging results

Spark reassures on safety of haemophilia gene therapy

https://pharmaphorum.com/news/spark-reassures-safety-haemophilia-gene-therapy/

Haematology is one of the most exciting areas in drug development today, with waves of new treatments emerging

CAR-Ts to take centre stage at ASH haematology congress

https://pharmaphorum.com/news/car-ts-take-centre-stage-haematology-congress/

ASH